Related Experiment Video
Updated: May 20, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
β-thalassemia intermedia: a clinical perspective
Khaled M Musallam1, Ali T Taher, Eliezer A Rachmilewitz
1Department of Medicine and Medical Specialties, IRCCS Cà Granda Foundation Maggiore Policlinico Hospital, 20122 Milan, Italy.
Abstract:
Our understanding of the molecular and pathophysiological mechanisms underlying the disease process in patients with β-thalassemia intermedia has substantially increased over the past decade. Earlier studies observed that patients with β-thalassemia intermedia experience a clinical-complications profile that is different from that in patients with β-thalassemia major. In this article, a variety of clinical morbidities are explored, and their associations with the underlying disease pathophysiology and risk factors are examined. These involve several organs and organ systems including the vasculature, heart, liver, endocrine glands, bone, and the extramedullary hematopoietic system. The effects of some therapeutic interventions on the development of clinical complications are also discussed.
Insights
Beta-thalassemia intermedia presents unique clinical complications compared to major forms. This review explores these morbidities, their pathophysiology, and treatment impacts.
Area of Science:
- Hematology
- Molecular Biology
- Pathophysiology
Background:
- Significant advancements in understanding beta-thalassemia intermedia mechanisms.
- Distinct clinical complication profiles observed in intermedia versus major beta-thalassemia.
Purpose of the Study:
- To explore clinical morbidities in beta-thalassemia intermedia.
- Examine associations between complications, pathophysiology, and risk factors.
- Discuss therapeutic interventions' effects on clinical complications.
Main Methods:
- Review of existing literature on beta-thalassemia intermedia.
- Analysis of clinical data and pathophysiological mechanisms.
- Exploration of organ system involvement and risk factors.
Main Results:
- Identified diverse clinical morbidities across multiple organ systems.
- Established links between pathophysiology and observed complications.
- Highlighted the influence of therapeutic interventions on complication development.
Conclusions:
- Beta-thalassemia intermedia necessitates a comprehensive understanding of its unique complications.
- Pathophysiology and risk factors are crucial for managing diverse clinical morbidities.
- Therapeutic strategies can impact the development and severity of complications.
Related Concept Videos
Type I Diabetes III: Clinical Manifestations
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Graves' Disease I: Introduction
Multiple Allele Traits
Chronic Kidney Disease II: Clinical Manifestations
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
